44 results
6-K
EX-99.1
GLPG
Galapagos NV
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
. This decrease was due to a lower increase in the percentage of completion, partly offset by a higher revenue recognition of milestone payments … ) program and reduced spend on our Toledo (SIKi) and TYK2 programs. This was partly offset by cost increases for our filgotinib program, on a six month
6-K
EX-99.1
GLPG
Galapagos NV
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
), MOR106 (atopic dermatitis), and GLPG1972 (OA), and reduced spend on our other programs. This was partly offset by cost increases for our filgotinib … in headcount and other operating expenses mainly driven by the commercial launch of filgotinib in Europe. This increase was partly offset by higher cost
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
. This was partly offset by an increase in costs related to the evolution of our CAR-T programs.
S&M and G&A expenses amounted to €134.0 million in 2023, compared … offset by an impairment of €7.6 million on a construction project in Mechelen, Belgium.
Other operating income (€47.3 million in 2023 compared to €36.1
6-K
EX-99.1
GLPG
Galapagos NV
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
explained by higher costs for CAR-T programs in oncology and filgotinib, partly offset by cost decrease in our SIKi program and other programs.
S&M … at amortized cost in U.S. dollars, partly offset by €2.9 million of positive changes in (fair) value of current financial investments.
Net other
6-K
EX-99.1
GLPG
Galapagos NV
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
dermatitis), and GLPG1972 (OA) programs and by reduced spend on our other programs. This was partly offset by costs increases for our filgotinib … . This net decrease was composed of (i) €376.7 million of operational cash burn, (ii) offset by €2.7 million of cash proceeds from capital and share
6-K
EX-99.1
hgr9yj yvk5
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
mx9m g1lazxjaupaz6
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
kdwsyw99ounj51
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
rrjyfurw
25 Oct 19
Solid third quarter 2019 performance with strong balance sheet for continued R&D growth
5:00pm
6-K
EX-99.1
ihb13a34cvq4x
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm
6-K
EX-99.2
ypnfdzlj
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.1
fp0c064z xi
11 May 20
Current report (foreign)
4:05pm
6-K
EX-99.1
70lwlzz
11 May 21
Current report (foreign)
2:10pm
6-K
EX-99.1
qub8 orkw013sas
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
mwg c8oyp
19 Feb 21
Pipeline and capital for growth
6:00am
6-K
EX-99.2
tjq 3xxmoq
9 Nov 20
Galapagos reports Q3 2020 results
4:01pm
6-K
EX-99.2
5jxl6l9gyofoy
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.2
5svleqkb0r1x8ixfdx
26 Apr 19
Galapagos reports on historic first quarter 2019
4:06pm
6-K
EX-99.1
8xdnt
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
6-K
EX-99
2j5va16l7jn
25 Jul 19
Strong clinical progress in H1, and transformative collaboration with Gilead announced
4:24pm